Sichuan Huiyu Pharmaceutical Co., Ltd. (SHA:688553)
China · Delayed Price · Currency is CNY 20.29
+0.24 (1.20%)
May 20, 2026, 11:29 AM CST
SHA:688553 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,019 | 988.46 | 1,085 | 926.02 | 1,490 | 1,820 |
Other Revenue | 9.69 | 9.69 | 9.01 | 1.06 | 3.27 | 3.44 |
| 1,028 | 998.14 | 1,094 | 927.08 | 1,493 | 1,824 | |
Revenue Growth (YoY) | -5.73% | -8.79% | 18.05% | -37.92% | -18.12% | 33.68% |
Cost of Revenue | 225.9 | 209 | 187.58 | 132.75 | 180.12 | 160.19 |
Gross Profit | 802.4 | 789.14 | 906.8 | 794.32 | 1,313 | 1,664 |
Selling, General & Admin | 454.95 | 456.29 | 511.56 | 437.58 | 810.82 | 972.32 |
Research & Development | 307.67 | 302.71 | 327.72 | 340.76 | 356.19 | 248.21 |
Other Operating Expenses | 9.52 | 9.43 | 6.57 | 6.72 | 7.83 | 9.57 |
Operating Expenses | 772.98 | 770.41 | 845.82 | 787.93 | 1,176 | 1,230 |
Operating Income | 29.41 | 18.73 | 60.98 | 6.39 | 136.66 | 433.49 |
Interest Expense | -11.33 | -9.78 | -12.4 | -6.7 | -1.18 | -1.06 |
Interest & Investment Income | 64.85 | 53.53 | 50.23 | 79.73 | 91.18 | 20.16 |
Currency Exchange Gain (Loss) | 6.29 | 6.29 | -0.78 | 3.33 | -0.13 | -1.1 |
Other Non Operating Income (Expenses) | -16.07 | -1.38 | 0.66 | 1.39 | -5.16 | -4.17 |
EBT Excluding Unusual Items | 73.16 | 67.4 | 98.69 | 84.13 | 221.37 | 447.31 |
Gain (Loss) on Sale of Investments | -112.84 | -167 | 239.86 | 6.44 | 2.33 | 6.16 |
Gain (Loss) on Sale of Assets | 0 | 0 | -0.3 | - | -0.03 | -0.02 |
Asset Writedown | -0.4 | -0.12 | -9.58 | - | - | - |
Other Unusual Items | 35.41 | 35.41 | 21.04 | 41.58 | 14.72 | 24.25 |
Pretax Income | -4.67 | -64.31 | 349.7 | 132.15 | 238.39 | 477.7 |
Income Tax Expense | -22.53 | -33.77 | 33.8 | -7.18 | -10.6 | 31.84 |
Earnings From Continuing Operations | 17.86 | -30.55 | 315.9 | 139.33 | 248.99 | 445.86 |
Minority Interest in Earnings | 4.68 | 5.59 | 9.49 | 0.45 | - | - |
Net Income | 22.53 | -24.96 | 325.39 | 139.79 | 248.99 | 445.86 |
Net Income to Common | 22.53 | -24.96 | 325.39 | 139.79 | 248.99 | 445.86 |
Net Income Growth | -91.11% | - | 132.78% | -43.86% | -44.16% | 29.87% |
Shares Outstanding (Basic) | 419 | 416 | 423 | 424 | 422 | 372 |
Shares Outstanding (Diluted) | 419 | 416 | 423 | 424 | 422 | 372 |
Shares Change (YoY) | -1.23% | -1.55% | -0.24% | 0.37% | 13.58% | 2.81% |
EPS (Basic) | 0.05 | -0.06 | 0.77 | 0.33 | 0.59 | 1.20 |
EPS (Diluted) | 0.05 | -0.06 | 0.77 | 0.33 | 0.59 | 1.20 |
EPS Growth | -90.99% | - | 133.33% | -44.07% | -50.83% | 26.32% |
Free Cash Flow | 27.98 | -14.76 | 114.78 | -229.79 | -267.55 | 12.91 |
Free Cash Flow Per Share | 0.07 | -0.04 | 0.27 | -0.54 | -0.63 | 0.04 |
Dividend Per Share | 0.200 | 0.200 | 0.463 | 0.213 | 0.235 | 0.211 |
Dividend Growth | -56.82% | -56.82% | 117.47% | -9.36% | 11.37% | - |
Gross Margin | 78.03% | 79.06% | 82.86% | 85.68% | 87.94% | 91.22% |
Operating Margin | 2.86% | 1.88% | 5.57% | 0.69% | 9.15% | 23.77% |
Profit Margin | 2.19% | -2.50% | 29.73% | 15.08% | 16.67% | 24.45% |
Free Cash Flow Margin | 2.72% | -1.48% | 10.49% | -24.79% | -17.92% | 0.71% |
EBITDA | 121.03 | 107.5 | 138.3 | 65.2 | 184.38 | 468.91 |
EBITDA Margin | 11.77% | 10.77% | 12.64% | 7.03% | 12.35% | 25.71% |
D&A For EBITDA | 91.62 | 88.76 | 77.32 | 58.81 | 47.72 | 35.43 |
EBIT | 29.41 | 18.73 | 60.98 | 6.39 | 136.66 | 433.49 |
EBIT Margin | 2.86% | 1.88% | 5.57% | 0.69% | 9.15% | 23.77% |
Effective Tax Rate | - | - | 9.67% | - | - | 6.67% |
Revenue as Reported | 1,028 | 998.14 | 1,094 | 927.08 | 1,493 | 1,824 |
Advertising Expenses | - | 4.5 | 1.27 | - | 1 | 3.71 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.